Results: 1-18 |
Results: 18

Authors: Mazurier, C Goudemand, J Hilbert, L Caron, C Fressinaud, E Meyer, D
Citation: C. Mazurier et al., Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology, BEST P R C, 14(2), 2001, pp. 337-347

Authors: Meyer, D Fressinaud, E Hilbert, L Ribba, AS Lavergne, JM Mazurier, C
Citation: D. Meyer et al., Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function, BEST P R C, 14(2), 2001, pp. 349-364

Authors: Poon, MC d'Oiron, R Hann, I Negrier, C de Lumley, L Thomas, A Karafoulidou, A Demers, C Street, A Huth-Kuhne, A Petrini, P Fressinaud, E Morfini, M Tengborn, L Marques-Verdier, A Musso, R Devecioglu, O Houston, DS Lethagen, S Van Geet, C von Depka, M Berger, C Beurrier, P Britton, HA Gerrits, W Guthner, C Kuhle, S Lorenzo, JJ Makris, PE Nohe, N Paugy, P Pautard, B Torchet, MF Trillot, N Vicariot, M Wilde, J Winter, M Chambost, H Ingerslev, J Peters, M Strauss, G
Citation: Mc. Poon et al., Use of recombinant factor VIIa (NovoSeven (R)) in patients with Glanzmann thrombasthenia, SEM HEMATOL, 38(4), 2001, pp. 21-25

Authors: Ruiz, C Liu, CY Sun, QH Sigaud-Fiks, M Fressinaud, E Muller, JY Nurden, P Nurden, AT Newman, PJ Valentin, N
Citation: C. Ruiz et al., A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alpha IIb beta 3) integrin receptorlocked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype, BLOOD, 98(8), 2001, pp. 2432-2441

Authors: Ribba, AS Hilbert, L Lavergne, JM Fressinaud, E Boyer-Neumann, C Ternisien, C Juhan-Vague, I Goudemand, J Girma, JP Mazurier, C Meyer, D
Citation: As. Ribba et al., The arginine-552-cysteine (R1315C) mutation within the Al loop of von Willebrand factor induces an abnormal folding with a loss of function resultingin type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor, BLOOD, 97(4), 2001, pp. 952-959

Authors: Veyradier, A Fressinaud, E Boyer-Neumann, C Trossaert, M Meyer, D
Citation: A. Veyradier et al., von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system, THROMB HAEM, 84(4), 2000, pp. 727-728

Authors: Veyradier, A Jenkins, CSP Fressinaud, E Meyer, D
Citation: A. Veyradier et al., Acquired von Willebrand syndrome: from pathophysiology to management, THROMB HAEM, 84(2), 2000, pp. 175-182

Authors: d'Oiron, R Menart, C Trzeciak, MC Nurden, P Fressinaud, E Dreyfus, M Laurian, Y Negrier, C
Citation: R. D'Oiron et al., Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing inversive procedures, THROMB HAEM, 83(5), 2000, pp. 644-647

Authors: Tout, H Obert, B Houllier, A Fressinaud, E Rothschild, C Meyer, D Girma, JP
Citation: H. Tout et al., Mapping and functional studies of two alloantibodies developed in patientswith type 3 von Willebrand disease, THROMB HAEM, 83(2), 2000, pp. 274-281

Authors: Costa, JM Vidaud, D Laurendeau, I Vidaud, M Fressinaud, E Moisan, JP David, A Meyer, D Lavergne, JM
Citation: Jm. Costa et al., Somatic mosaicism and compound heterozygosity in female hemophilia B, BLOOD, 96(4), 2000, pp. 1585-1587

Authors: Jorieux, S Fressinaud, E Goudemand, J Gaucher, C Meyer, D Mazurier, C
Citation: S. Jorieux et al., Conformational changes in the D ' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment, BLOOD, 95(10), 2000, pp. 3139-3145

Authors: Zini, JM Durocher, A Blettery, B Fonlupt, J Hofliger, P Laurian, Y Mangola, B Roubertie, E Sultan, Y Vicariot, M Delobel, J Derlon, A Ducluzeau, R Fressinaud, E Gaillard, S Guerin, V Guerois, C Klotz, P Lauroua, P Lorenzini, JL Murat, I Oberling, F Perrimond, H Pierre-Louis, S Pouzol, P Richard, D Rotschild, C Simon, N Subtil, E Tron, P Brucker, P Cordier, H Dindaine, ML
Citation: Jm. Zini et al., Emergency management of hemophiliacs with suspected hemorrhage, PRESSE MED, 28(11), 1999, pp. 591-595

Authors: Obert, B Tout, H Veyradier, A Fressinaud, E Meyer, D Girma, JP
Citation: B. Obert et al., Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF, THROMB HAEM, 82(5), 1999, pp. 1382-1385

Authors: Veyradier, A Fressinaud, E Sigaud, M Wolf, M Meyer, D
Citation: A. Veyradier et al., A new automated method for von Willebrand factor antigen measurement usinglatex particles, THROMB HAEM, 81(2), 1999, pp. 320-321

Authors: Janel, N Leroy, C Laude, I Toti, F Fressinaud, E Meyer, D Freyssinet, JM Kerbiriou-Nabias, D
Citation: N. Janel et al., Assessment of the expression of candidate human plasma membrane phospholipid scramblase in Scott syndrome cells, THROMB HAEM, 81(2), 1999, pp. 322-323

Authors: Fressinaud, E Veyradier, A Sigaud, M Boyer-Neumann, C Le Boterff, C Meyer, D
Citation: E. Fressinaud et al., Therapeutic monitoring of von Willebrand disease: interest and limits of aplatelet function analyser at high shear rates, BR J HAEM, 106(3), 1999, pp. 777-783

Authors: Martinez, MC Martin, S Toti, F Fressinaud, E Dachary-Prigent, J Meyer, D Freyssinet, JM
Citation: Mc. Martinez et al., Significance of capacitative Ca2+ entry in the regulation of phosphatidylserine expression at the surface of stimulated cells, BIOCHEM, 38(31), 1999, pp. 10092-10098

Authors: Veyradier, A Fressinaud, E Meyer, D
Citation: A. Veyradier et al., Laboratory diagnosis of von Willebrand disease, INT J CL L, 28(4), 1998, pp. 201-210
Risultati: 1-18 |